STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBDDan Turner, Axel Dignaß, Amanda Ricciuto et al.|Gastroenterology|2021Cited by 2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-TargetLaurent Peyrin‐Biroulet, Péter L. Lakatos, Edward V. Loftus et al.|The American Journal of Gastroenterology|2015Cited by 1.8k
Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT RegistryGary R. Lichtenstein, William J. Sandborn|Clinical Gastroenterology and Hepatology|2006Cited by 906
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative ColitisWilliam J. Sandborn, Wojciech Niezychowski|New England Journal of Medicine|2012Cited by 794